CPIX Form 4: Caroline Young purchases shares under 10b5-1 plan
Rhea-AI Filing Summary
Caroline Young, a director of Cumberland Pharmaceuticals Inc. (CPIX), purchased shares of the company in multiple automatic trades executed during July 2025 under a Rule 10b5-1 trading plan adopted on November 14, 2024. The reported purchases occurred across trading dates from July 1 through July 31, 2025, at per-share prices ranging about $3.05 to $3.82. Following the reported transactions, her beneficial ownership increased from 32,661 shares to 32,821 shares, a net gain of 160 shares.
The filing confirms the trades were made pursuant to the pre-established 10b5-1 plan and signed by an attorney-in-fact on behalf of the reporting person. No sales, derivative transactions, or other changes in relationship to the issuer are reported in this Form 4.
Positive
- Insider purchases executed under a Rule 10b5-1 plan, providing an affirmative-defense framework for the trades.
- Beneficial ownership increased by 160 shares, from 32,661 to 32,821 shares, all acquired in July 2025.
- Purchase prices disclosed for each trade, ranging approximately between $3.05 and $3.82 per share, improving transparency.
Negative
- None.
Insights
TL;DR: Director purchases were routine automatic executions under a 10b5-1 plan, resulting in a small increase in beneficial ownership to 32,821 shares.
The Form 4 documents a sequence of small, daily purchases in July 2025 executed under a Rule 10b5-1 plan adopted November 14, 2024. Transaction prices reported range roughly from $3.05 to $3.82 per share. The incremental increase of 160 shares is immaterial to market capitalization but is a clear, documented instance of insider buying under an affirmative-defense trading plan. There are no reported dispositions or derivative positions disclosed.
TL;DR: The filing reflects standard governance-compliant insider trading via a certified 10b5-1 plan with attorney-in-fact signature, showing orderly purchases only.
The report states the purchases were automatic pursuant to a Rule 10b5-1 plan, which provides an affirmative defense to insider trading allegations when properly adopted. The signature by an attorney-in-fact is documented. The pattern shows multiple small acquisitions over one month with no accompanying disclosures of sales or option exercises, consistent with plan-driven executions rather than ad hoc trading.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 6 | $3.50 | $21.00 |
| Purchase | Common Stock | 6 | $3.55 | $21.30 |
| Purchase | Common Stock | 6 | $3.33 | $19.98 |
| Purchase | Common Stock | 6 | $3.47 | $20.82 |
| Purchase | Common Stock | 8 | $3.37 | $26.96 |
| Purchase | Common Stock | 8 | $3.55 | $28.40 |
| Purchase | Common Stock | 8 | $3.54 | $28.32 |
| Purchase | Common Stock | 8 | $3.47 | $27.76 |
| Purchase | Common Stock | 8 | $3.45 | $27.60 |
| Purchase | Common Stock | 8 | $3.59 | $28.72 |
| Purchase | Common Stock | 8 | $3.82 | $30.56 |
| Purchase | Common Stock | 8 | $3.79 | $30.32 |
| Purchase | Common Stock | 8 | $3.45 | $27.60 |
| Purchase | Common Stock | 8 | $3.46 | $27.68 |
| Purchase | Common Stock | 8 | $3.21 | $25.68 |
| Purchase | Common Stock | 8 | $3.20 | $25.60 |
| Purchase | Common Stock | 8 | $3.05 | $24.40 |
| Purchase | Common Stock | 8 | $3.06 | $24.48 |
| Purchase | Common Stock | 8 | $3.23 | $25.84 |
| Purchase | Common Stock | 8 | $3.531 | $28.25 |
| Purchase | Common Stock | 8 | $3.52 | $28.16 |
| Purchase | Common Stock | 8 | $3.56 | $28.48 |
Footnotes (1)
- [object Object]
